信隆健康（002105）发布2025年度利润分配预案，全年亏损致不派发红利
主要内容摘要：
- 2025年度亏损： 深圳信隆健康产业发展股份有限公司（简称“信隆健康”）2025年度合并报表归属于上市公司股东的净利润为人民币-64,114,657.08元。
- 累计可分配利润： 虽然公司本年度亏损，但截至2025年末，累计可供股东分配的利润仍有人民币320,770,760.53元，母公司层面为人民币481,865,177.58元。
- 利润分配预案： 公司2025年度不派发现金红利、不送红股，也不以资本公积转增股本，未分配利润将用于补充流动资金。
- 三年内分红情况： 最近三个会计年度内，仅有2023年度派发过一次现金红利，金额为11,044,800元，2024和2025年均未分红。
- 风险警示： 公司不触及深圳证券交易所股票上市规则第9.8.1条规定的其他风险警示情形。
- 董事会决议： 该预案已于2026年4月22日董事会会议审议通过，尚需提交2025年度股东大会审议。
对投资者的重要提示与潜在影响：
- 利润分配缺失或影响市场预期： 公司连续两年不派发现金红利，反映出经营压力和盈利能力下滑，可能对希望通过分红获得回报的投资者造成负面影响。
- 充足未分配利润但选择不分红： 尽管账面上仍有超过3亿元可供分配利润，但公司为保障经营和现金流安全选择不分配，显示管理层对未来市场环境或自身运营的不确定性有较高预期。
- 公司经营压力加大： 连续年度亏损，且2025年亏损幅度较2024年大幅扩大（2024年净利润为-18,933,887.07元），这对公司长期发展、融资能力和市场信心均可能带来压力。
- 未触及强制性风险警示： 公司未进入被实施其他风险警示的行列，短期内不会被ST等风险标签影响交易。
- 流动资金安全优先： 管理层表示将未分配利润用于补充公司流动资金，有利于保障公司运营和抗风险能力，但也意味着短期内回报投资者的能力有限。
详细内容：
信隆健康于2026年4月22日发布2025年度利润分配预案公告。公告显示，公司2025年全年实现归属于上市公司股东的净利润为-64,114,657.08元，呈现明显亏损状态。加上前期滚存未分配利润，2025年末累计可供分配利润为320,770,760.53元，母公司报表口径下更高达481,865,177.58元。
本次董事会决议，公司2025年度不派发现金红利、不送红股，也不进行资本公积金转增股本，未分配利润将全部用于补充公司流动资金，旨在提升公司抗风险能力和维持正常经营。
值得注意的是，信隆健康近三年仅有2023年度进行过现金分红，2024、2025年均未分红，且公司表示该决定符合公司章程和披露的股东回报规划。公司也未触及深交所第9.8.1条风险警示情形，短期内仍保持正常上市状态。
该利润分配预案已获独立董事专门会议和董事会通过，尚需2025年度股东大会进一步审议批准。
投资者需关注：
- 连续年度亏损与不分红会影响市场信心和股价表现，投资者需警惕相关风险。
- 公司账面利润充足但选择保守分配策略，反映出管理层对未来经营环境的谨慎态度。
- 短期内公司不会被实施特别风险警示，但长期盈利修复和分红恢复将是关注重点。
后续进展： 建议持续关注2025年度股东大会对该预案的审议结果，以及公司未来经营和分红政策变化。
免责声明：
本文内容仅供参考，不构成任何投资建议。投资者应充分了解相关风险，依据自身判断及专业机构意见谨慎决策。本文信息来自公司公开披露文件，因市场变化或公司经营调整，相关内容或有变动，敬请关注后续公告。
Xinglong Health (002105) Releases 2025 Profit Distribution Plan: No Dividend Due to Annual Loss
Key Takeaways:
- 2025 Loss: Shenzhen Xinglong Health Industry Development Co., Ltd. (“Xinglong Health”) reported a net loss attributable to shareholders of RMB -64,114,657.08 for 2025.
- Undistributed Profits: Despite the annual loss, the company still has RMB 320,770,760.53 in undistributed profits as of the end of 2025, and RMB 481,865,177.58 at the parent company level.
- Profit Distribution Plan: No cash dividend, no bonus shares, and no capital reserve conversion into share capital for 2025. Undistributed profits will be used to supplement working capital.
- Dividend Record in Past Three Years: Only one cash dividend paid in the last three years (2023: RMB 11,044,800); no dividends for 2024 or 2025.
- Risk Warning: The company does not trigger any other risk warning conditions under SZSE Stock Listing Rule 9.8.1.
- Board Approval: The plan was approved by the board on April 22, 2026, and still awaits shareholder approval at the 2025 AGM.
Important Shareholder Notes & Potential Price Sensitivity:
- Lack of Dividend May Affect Expectations: No cash dividend for two consecutive years reflects operational pressure and declining profitability, which may disappoint investors seeking returns.
- Retaining Ample Profits: Although significant undistributed profits remain, management prefers to retain profits to support operations, indicating caution about future uncertainties.
- Increasing Operating Pressure: The loss for 2025 is much greater than 2024 (-18.9 million), suggesting growing challenges for the company’s long-term development and market confidence.
- No Forced Risk Warnings: The company is not subject to ST or similar tags; normal trading continues for now.
- Focus on Working Capital: Undistributed profits will bolster liquidity and risk resilience but limit near-term investor returns.
Details:
On April 22, 2026, Xinglong Health’s board released its 2025 profit distribution plan, revealing a net loss of RMB -64,114,657.08 for the year. Despite this, undistributed profits stood at RMB 320.77 million at the end of 2025, and RMB 481.87 million at the parent company level.
The board decided that there would be no cash dividend, bonus share issuance, or capital reserve conversion for 2025. All undistributed profits will support working capital needs, aiming to ensure stable operations and enhance risk resilience.
Notably, only one cash dividend has been paid in the past three years (2023), with none in 2024 or 2025. Management asserts that this aligns with company policy and shareholder return plans. The company does not meet the criteria for SZSE’s additional risk warnings, so it remains in normal trading status.
This plan has been approved by independent directors and the board but still requires shareholder approval at the 2025 AGM.
Investor Focus:
- Ongoing losses and no dividend may impact market sentiment and share price performance—investors should remain vigilant.
- Management’s conservative approach despite sufficient profits highlights caution about future business conditions.
- While no immediate risk warnings, future recovery of profitability and dividend resumption are key watchpoints.
Next Steps: Investors should monitor the outcome of the 2025 AGM and any future policy changes regarding profit distribution.
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Investors should fully understand associated risks and consult professional sources before making decisions. Information is based on public disclosures and may change with market conditions or company operations. Please follow future announcements.
View 信隆健康 Historical chart here
